Who is on it, and how far along Every drug ChEMBL records acting on PARC, by the furthest stage it has reached for any use, coloured by modality.
How to read this Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
Approved9 Moxifloxacin Moxifloxacin SponsorBayer ModalitySmall molecule ActionInhibitor Open trials65 Ciprofloxacin Ciprofloxacin SponsorIterum Therapeutics, International Limited ModalitySmall molecule ActionInhibitor Open trials56 Delafloxacin Delafloxacin SponsorMelinta Therapeutics ModalitySmall molecule ActionInhibitor Open trials1 Norfloxacin Norfloxacin SponsorMerck & Co. (MSD) ModalitySmall molecule ActionInhibitor Open trials1 Alatrofloxacin Alatrofloxacin SponsorPfizer ModalitySmall molecule ActionInhibitor Open trials0 Besifloxacin Besifloxacin SponsorBausch & Lomb ModalitySmall molecule ActionInhibitor Open trials0 Garenoxacin Garenoxacin SponsorNot known ModalitySmall molecule ActionInhibitor Open trials0 Sparfloxacin Sparfloxacin SponsorViatris ModalitySmall molecule ActionInhibitor Open trials0 Trovafloxacin Trovafloxacin SponsorPfizer ModalitySmall molecule ActionInhibitor Open trials0 Phase 36 Gepotidacin Gepotidacin SponsorGSK ModalitySmall molecule ActionInhibitor Open trials3 Nadifloxacin Nadifloxacin SponsorNot known ModalitySmall molecule ActionInhibitor Open trials1 Nemonoxacin Nemonoxacin SponsorTaiGen Biotechnology Co., Ltd. ModalitySmall molecule ActionInhibitor Open trials1 Prulifloxacin Prulifloxacin SponsorLee's Pharm ModalitySmall molecule ActionInhibitor Open trials0 Sitafloxacin anhydrous Sitafloxacin anhydrous SponsorNot known ModalitySmall molecule ActionInhibitor Open trials0 Zabofloxacin Zabofloxacin SponsorDong Wha Pharmaceutical Co. Ltd. ModalitySmall molecule ActionInhibitor Open trials0 Phase 24 Rifaquizinone Rifaquizinone SponsorTenNor Therapeutics (Suzhou) ModalitySmall molecule ActionInhibitor Open trials2 Pefloxacin Pefloxacin SponsorNot known ModalitySmall molecule ActionInhibitor Open trials1 Acorafloxacin Acorafloxacin SponsorFuriex Pharmaceuticals, Inc ModalitySmall molecule ActionInhibitor Open trials0 Pradofloxacin Pradofloxacin SponsorNot known ModalitySmall molecule ActionInhibitor Open trials0
Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials. All act as: Topoisomerase IV inhibitor. The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 26 in all, from ClinicalTrials.gov. Trial Drug Phase Status Lead sponsor First posted Randomized, Multicenter, Non-inferiority Trial Comparing the Efficacy of Fosfomycin Versus Fluoroquinolones or Cotrimoxazole as Oral Follow-up Treatment in Febrile Urinary Tract Infections in Men Caused by Susceptible Enterobacteria Ciprofloxacin Phase 3 Not yet recruiting Assistance Publique - Hôpitaux de Paris Nov 12, 2026 A Study to Evaluate the Effects of Therapeutic and Supratherapeutic Doses of KRP-S124 Compared to Placebo With Moxifloxacin on QTc Interval in Healthy Participants Moxifloxacin Phase 1 Recruiting Kyorin Pharmaceutical Co.,Ltd Nov 5, 2026 Phase 1 Study to Assess the Effects of HSK31858 on the QT/QTc Interval in Healthy Chinese Participants Moxifloxacin Phase 1 Recruiting Haisco Pharmaceutical Group Co., Ltd. Nov 4, 2026 Comparing Nadifloxacin Plus Tretinoin Versus Clindamycin Plus Tretinoin Creams for Mild-to-Moderate Acne Nadifloxacin Phase 4 Recruiting Nishtar Medical University Nov 4, 2026 Curcumin Extract Added to Ciprofloxacin for Typhoid Carriers Among Food Handlers of the Free Nutritious Meal Program Ciprofloxacin Phase 2 Not yet recruiting Universitas Sebelas Maret Oct 30, 2026 Fluoroquinolone-Doxycycline Oral Treatments for Adults With Uncomplicated Brucellosis Moxifloxacin Not applicable Not yet recruiting The First Affiliated Hospital of Shihezi University Oct 21, 2026 All-Oral Fluoroquinolone-Based Triple Therapies for Adults With Imaging-Confirmed Osteoarticular Brucellosis Moxifloxacin Not applicable Not yet recruiting The First Affiliated Hospital of Shihezi University Oct 21, 2026 A Single and Multiple Ascending Dose Study of EPX-100 in Healthy Adult Participants Moxifloxacin Phase 1 Recruiting Epygenix Oct 16, 2026 Comparison of Postoperative Pain After Double Antibiotic Paste vs Calcium Hydroxide in Teeth With Symptomatic Apical Periodontitis Ciprofloxacin Not applicable Recruiting College of Physicians and Surgeons Pakistan Oct 9, 2026 A Phase 2b Study to Evaluate the Efficacy, Safety, and PK Profiles of TNP-2092 Administered Via IA Injection in PJI Participants Rifaquizinone Phase 2 Recruiting TenNor Therapeutics (Zhongshan) Limited Oct 5, 2026 Efficacy and Safety of Second-Line Helicobacter Pylori Eradication Moxifloxacin Not applicable Active, not recruiting Seoul National University Bundang Hospital Oct 2, 2026 Prospective Registry of Exposure to Gepotidacin (PREG) Gepotidacin — Recruiting GlaxoSmithKline Sep 30, 2026 Intracameral Levofloxacin Versus Moxifloxacin After Cataract Surgery Moxifloxacin Not applicable Not yet recruiting Assiut University Sep 30, 2026 Restrictive Versus Standard Antibiotic Treatment During CAR-T Therapy Ciprofloxacin Phase 2 Not yet recruiting Zealand University Hospital Sep 25, 2026 Acetic Acid Ear Drops Versus 0.3 % Ciprofloxacin for Chronic Suppurative Otitis Media. Ciprofloxacin Not applicable Not yet recruiting Dow University of Health Sciences Sep 22, 2026 Moxifloxacin Versus Clindamycin in the Management of Odontogenic Maxillofacial Infectious Processes Moxifloxacin Not applicable Not yet recruiting Nishtar Medical University Sep 9, 2026 Population Pharmacokinetic Model of Rifampicin in Staphylococcal Osteoarticular Infections Ciprofloxacin Not applicable Recruiting Groupe Hospitalier Diaconesses Croix Saint-Simon Aug 26, 2026 Drug-induced Crystalluria in Sulfamethoxazole, High Dose Ciprofloxacin and High Dose Amoxicillin Ciprofloxacin Not applicable Recruiting Universitair Ziekenhuis Brussel Aug 19, 2026 Silver Nanoparticle-Reinforced Double Antibiotic Paste in Symptomatic Apical Periodontitis: A Randomized Controlled Trial Ciprofloxacin Not applicable Not yet recruiting All India Institute of Medical Sciences Aug 13, 2026 A Study to Evaluate Gepotidacin Exposure in Breast Milk of Healthy Lactating Women Gepotidacin Phase 1 Recruiting GlaxoSmithKline Jun 12, 2026 Delafloxacin Plasma and Tissue Concentration in Patients With Skin, Soft Tissue, and Bone and Joint Infections. Delafloxacin — Not yet recruiting IRCCS San Raffaele Feb 23, 2026 A Study in Pediatric Participants Aged ≥2 to <12 Years With a Suspected or Confirmed Bacterial Infection or Receiving Prophylaxis Antibiotics Gepotidacin Phase 1 Not yet recruiting GlaxoSmithKline Jan 28, 2026 Comparative Analysis of Nemonoxacin and Other Anti-methicillin Resistant Staphylococcus Aureus (Anti-MRSA) Antimicrobial Therapy in Patients With Complicated Skin and Soft Tissue Infections (cSSTI): a Retrospective Chart Review Study Nemonoxacin — Active, not recruiting National Taiwan University Hospital May 6, 2025 A Phase 1/2 Study to Evaluate the Safety, PK and Efficacy of TNP-2092 Administered Via IA Injection in PJI Participants Rifaquizinone Phase 1 / Phase 2 Recruiting TenNor Therapeutics Inc. Mar 21, 2025 Clinical Markers of Dysphagia in Cardiac Surgical Patients Pefloxacin — Active, not recruiting University of Florida Mar 31, 2022 Norfloxacin With Itopride Versus Norfloxacin in Secondary Prophylaxis of Spontaneous Bacterial Peritonitis Norfloxacin Phase 3 Recruiting Tanta University Nov 13, 2019
Show all 26Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL2363076 , ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov , checked daily; this page as of 2026-11-21. ChEMBL and Open Targets